Cercar
01/04/2023
The immunoregulatory role of IL-35 in patients with interstitial lung disease
Osuna-Gomez, R, Barril, S, Mulet, M, Atenza, CZ, Millan-Billi, P, Pardessus, A, Brough, DE, Sabzevari, H, Semnani, RT, Castillo, D, Vidal, S. The immunoregulatory role of IL-35 in patients with interstitial lung disease. IMMUNOLOGY. 2023; 168(4)DOI:10.1111/imm.13596. PMID:36273280. IF:4.900(Q2/3D).
01/04/2023
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry
Dobarro, D, Donoso-Trenado, V, Sole-Gonzalez, E, Moliner-Abos, C, Garcia-Pinilla, JM, Lopez-Fernandez, S, Ruiz-Bustillo, S, Diez-Lopez, C, Castrodeza, J, Mendez-Fernandez, AB, Vaqueriza-Cubillo, D, Cobo-Marcos, M, Tobar, J, Sagasti-Aboitiz, I, Rodriguez, M, Escolar, V, Abecia, A, Codina, P, Gomez-Otero, I, Pastor, F, Marzoa-Rivas, R, Gonzalez-Babarro, E, de Juan-Baguda, J, Melendo-Viu, M, de Frutos, F, Gonzalez-Costello, J. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Failure. 2023; 10(2)DOI:10.1002/ehf2.14278. PMID:36655614. IF:3.200(Q2/3D).
01/04/2023
Placental site trophoblastic tumor (PSTT): a case report and review of the literature
Zampacorta, C, Pasciuto, MP, Ferro, B, Lucidi, A, Maestro, AS, Espinosa, I, D'Angelo, E, Prat, J. Placental site trophoblastic tumor (PSTT): a case report and review of the literature. Pathologica. 2023; 115(2)DOI:10.32074/1591-951X-873. PMID:37114629. IF:(Q/D).
01/04/2023
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A.E., Larson R.A., Podoltsev N.A., Strickland S., Wang E.S., Atallah E., Schiller G.J., Martinelli G., Neubauer A., Sierra J., Montesinos P., Recher C., Yoon S.-S., Maeda Y., Hosono N., Onozawa M., Kato T., Kim H.-J., Hasabou N., Nuthethi R., Tiu R., Levis M.J.. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy. 2023; 29(4)DOI:10.1016/j.jtct.2022.12.006. PMID:36526260. IF:3.600(Q1/3D).
01/04/2023
Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism
Martin-Fernandez, L, Garcia-Martinez, I, Lopez, S, Martinez-Perez, A, Vilalta, N, Plaza, M, Moret, C, Vinuela, A, Brown, AA, Panousis, NI, Buil, A, Dermitzakis, ET, Corrales, I, Souto, JC, Vidal, F, Soria, JM. Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism. THROMBOSIS AND HAEMOSTASIS. 2023; 123(04)DOI:10.1055/s-0043-1760844. PMID:36696913. IF:5.000(Q1/2D).
01/04/2023
Latest report from the ALTAMIRA study of emergency management of vein thrombosis: our departments' strengths and weaknesses
Matamoros J.F.. Latest report from the ALTAMIRA study of emergency management of vein thrombosis: our departments' strengths and weaknesses. EMERGENCIAS. 2023; 35(2)DOI:. PMID:37038937. IF:5.400(Q1/1D).
01/04/2023
An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice
Mir, JF, Rodriguez-Caba, C, Estrada-Campmany, M, de Gamarra-Martinez, EF, Mangues, MA, Bagaria, G, Riera, P. An Integrated Multidisciplinary Circuit Led by Hospital and Community Pharmacists to Implement Clopidogrel Pharmacogenetics in Clinical Practice. Pharmacy. 2023; 11(2)DOI:10.3390/pharmacy11020076. PMID:37104082. IF:(Q/D).
01/04/2023
A systematic review and meta-analysis of robot-assisted vs. open radical cystectomy: where do we stand and future perspective
Fallara, G, DI Maida, F, Bravi, CA, DE Groote, R, Piramide, F, Turri, F, Andras, I, Moschovas, M, Larcher, A, Breda, A, Dell'Oglio, P. A systematic review and meta-analysis of robot-assisted vs. open radical cystectomy: where do we stand and future perspective. Minerva Urology And Nephrology. 2023; 75(2)DOI:10.23736/S2724-6051.23.05065-6. PMID:36999835. IF:4.900(Q1/2D).